UPCC 05418: A Multicenter Double-Blind Randomized Placebo-Controlled Phase

Build status - In Progress

$UPCC 05418: A Multicenter Double-Blind Randomized Placebo-Controlled Phase III Study of Idasanutlin an MDM2 Antagonist with Cytarabine Versus Cytarabine Plus Placebo in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)$

Enrolling By Invitation

99 years or below

All

Phase 3

10 participants needed

1 Location

Brief description of study

The purpose of this study is to compare the effects, good or bad, of idasanutlin plus cytarabine (chemotherapy) versus placebo (an inactive substance that looks like idasanutlin) plus cytarabine on patients with relapsed or refractory Acute Myeloid Leukemia (AML) to find out which is better.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: ['Leukemia, Myeloid, Acute']
Age: 99 years or below
Gender: All

Updated on 04 Aug 2024. Study ID: 829461

If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research